<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817815</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2015/21</org_study_id>
    <nct_id>NCT02817815</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation and Characterization of Blood Platelet</brief_title>
  <acronym>FAPS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arterial thromboembolism constitutes a major risk of atrial fibrillation (AF) requiring
      antithrombotic therapy. Platelets and microparticles (MPs) are important for hemostasis and
      thrombosis, their role during AF is not well known. The principal objective of this study is
      to compare morphologic, functional and proteomics characteristics of blood platelet between
      AF patients and healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AF is associated with decreased quality of life and an increased risk of thromboembolic
      events. AF is the leading cause of embolic stroke. Identification of factors that may
      influence blood coagulability in these patients could better identify therapeutic targets to
      optimize anticoagulation. Platelets play a major role in the coagulation process, their study
      may provide valuable information. Moreover microparticles from platelet activation are known
      to have pathophysiological effects including effects on thrombosis and inhibition of
      fibrinolysis. It has also been shown that the microparticles have a role in endothelial
      dysfunction and generation of inflammatory condition which are associated with atrial
      fibrillation.

      Investigators propose in this project, a comparative study between AF patients and healthy
      volunteers. Complete characterization of platelet (morphology, platelet function, platelet
      proteome) and microparticles levels will be perform. Different site blood sampling (systemic
      or cardiac) will be done in patients during their ablation procedure. Patients will be
      followed during their hospitalisation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of maximal aggregation level (expressed in aggregation percentage) after ex vivo stimulation by Adenosine Di-Phosphate (ADP), arachidonic acid, ristocetin, collagen and Thrombin Receptor Activating Peptide (TRAP-6mers)</measure>
    <time_frame>Day 1</time_frame>
    <description>Aggregation percentage is measured by the method of light transmission aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of maximal disaggregation level (expressed in disaggregation percentage)</measure>
    <time_frame>Day 1</time_frame>
    <description>Disaggregation percentage is measured by the method of light transmission aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of platelet volume mean</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the Platelet morphology (shape change)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the modification of the membrane receptor expression modification</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of platelet proteins differentially expressed between groups</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Tissue Factor (TF) dependent microparticles level</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of fibrinolytic microparticles level</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxysmal AF patients in sinus rhythm the day of inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxysmal AF patients in atrial fibrillation the day of inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Persistent AF patients in sinus rhythm the day of inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Persistent AF patients in atrial fibrillation the day of inclusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrocardiogram (ECG)</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling from the cephalic vein</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling from the femoral vein</intervention_name>
    <description>Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>First blood sampling from left atrium</intervention_name>
    <description>Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial stimulation</intervention_name>
    <description>Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Second blood sampling from left atrium</intervention_name>
    <description>After 20min of continuous AF, a blood sampling from left atrium will be done</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria: valid for all groups

               -  Age superior or equal to 18 years old, both genders.

               -  Patient affiliated or recipient of a social welfare regimen.

               -  Patient's write agreement for study participation after reading information note

          -  Inclusion Criteria: specific for groups

        Group 1:

          -  Volunteers without heart disease.

          -  Volunteers who never had AF and not in AF the day of inclusion. Group 2

          -  Patient suffering of paroxysmal atrial fibrillation since at least 6 month and
             addressed for primo ablation of atrial fibrillation.

          -  Patient in sinus rhythm the day of inclusion. Group 3

          -  Patient suffering of paroxysmal atrial fibrillation since at least 6 month and
             addressed for primo ablation of atrial fibrillation.

          -  Patient in atrial fibrillation the day of inclusion Group 4

          -  Patient suffering of persistent atrial fibrillation since at least 6 month and
             addressed for primo ablation of atrial fibrillation.

          -  Patient in sinus rhythm the day of inclusion. Group 5

          -  Patient suffering of persistent atrial fibrillation since at least 6 month and
             addressed for primo ablation of atrial fibrillation.

          -  Patient in atrial fibrillation the day of inclusion

        Exclusion Criteria:

          -  Age &lt;18 years.

          -  Active smoker (&gt; 10 cigarettes/days)

          -  Pregnant woman or breastfeeding women or not receiving effective contraception.

          -  Volunteer participating in another interventional study requiring taking drug.

          -  Volunteer having taken antinflammatory, platelet anti-aggregant or calcium-channel
             blocker drugs within 8 days prior to inclusion

          -  Valvular heart diseases.

          -  Chronic inflammatory diseases.

          -  Cardiovascular event or stroke within 3 month prior to inclusion

          -  Uncontrolled hypertension

          -  Chronic hepatic or renal diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frédéric SACHER, Dr</last_name>
    <phone>(0)5 57 65 64 71</phone>
    <phone_ext>+33</phone_ext>
    <email>frederic.sacher@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion LEFEVRE</last_name>
    <phone>(0)5 57 62 30 91</phone>
    <phone_ext>+33</phone_ext>
    <email>marion.lefevre@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Electrophysiologie et de stimulation cardiaque / LIRYC - Hôpital Cardiologique du Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric SACHER, Dr</last_name>
      <phone>0()5 57 65 64 71</phone>
      <phone_ext>+33</phone_ext>
      <email>frederic.sacher@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marion LEFEVRE</last_name>
      <phone>(0)5 57 62 30 91</phone>
      <phone_ext>+33</phone_ext>
      <email>marion.lefevre@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Frédéric SACHER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélèze HOCINI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre JAIS, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas DERVAL, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud DENIS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation, blood platelet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

